Ganesh Shanmugam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ganesh Shanmugam has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Keith Buchan
Department of Cardiothoracic Surgery, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, Scotland, UK
2 shared publicationsBlaine Kent
Department of Anaesthesiology, QEII Health Sciences Centre, Halifax Infirmary, 1796 Summer Street, Halifax, Nova Scotia B3L 4P7, Canada
1 shared publicationGyaandeo Maharajh
1 shared publicationIan Colquhoun
Department of Cardio-Thoracic Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom
1 shared publicationRoger Baskett
Department of Cardiac Surgery, QEII Health Sciences Centre, Halifax Infirmary, 1796 Summer Street, Halifax, Nova Scotia B3L 4P7, Canada
1 shared publicationTurki Alsaiwadi
Department of Internal Medicine, QEII Health Sciences Centre, Halifax Infirmary, 1796 Summer Street, Halifax, Nova Scotia B3L 4P7, Canada
1 shared publication
Latest Publications
- Open Access
- 28 November 2011
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 41 (3) , 722-723
Management strategies in aortic coarctation
- 28 November 2011
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 41 (3) , 722-723
Open AccessManagement strategies in aortic coarctation
- Open Access
- 16 April 2008
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 7 (4) , 656-657
Serotonin syndrome following cardiac surgery
Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat depression. We report a case of serotonin syndrome following cardiac surgery
- 16 April 2008
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 7 (4) , 656-657
Open AccessSerotonin syndrome following cardiac surgery
Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat depression. We report a case of serotonin syndrome following cardiac surgery
- 1 August 2007
- Published by SAGE Publications in Asian Cardiovascular and Thoracic Annals
- Vol. 15 (4) , e46-e48
Left Atrial Malignant Mesenchymoma — Emergency Resection and Mitral Replacement
Cardiac mesenchymoma is a rare malignancy with a dismal prognosis. We present a case of left atrial mesenchymoma, obstructing the mitral orifice. An emergent tumor resection with mitral valve replacement was performed. Few reports deal with emergency resection of cardiac malignancies with mitral valve replacement. Surgery is the only effective treatment modality.
- 1 August 2007
- Published by SAGE Publications in Asian Cardiovascular and Thoracic Annals
- Vol. 15 (4) , e46-e48
Left Atrial Malignant Mesenchymoma — Emergency Resection and Mitral Replacement
Cardiac mesenchymoma is a rare malignancy with a dismal prognosis. We present a case of left atrial mesenchymoma, obstructing the mitral orifice. An emergent tumor resection with mitral valve replacement was performed. Few reports deal with emergency resection of cardiac malignancies with mitral valve replacement. Surgery is the only effective treatment modality.
- 1 June 2006
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 29 (6) , 925-932
Primary cardiac sarcoma
Primary malignant lesions of the heart are rare. Although myxomas have been extensively described, there is a paucity of large studies on non-myxomatous cardiac tumours. On the other hand, there are several case reports on specific histopathological variants, in small numbers. Consequently there exists no consensus on therapeutic modalities for cardiac sarcomas. The prognosis for these lesions remains dismal, despite the enhanced diagnostic ability of newer technology. The reasons for the dismal prognosis are (1) the advanced tumour stage at presentation, (2) non-specific symptomatolgy, (3) insufficient awareness of these lesions, due to their rarity, (4) delayed diagnosis and/or misdiagnosis, which leads to (5) advanced tumour stage at presentation. Thus a vicious cycle is created. This article addresses these issues, deals with the surgically relevant modes of presentation, rather than the histopathology, and reviews the diagnosis and management options for the various sarcomas, categorized by the site and extent of cardiac involvement. Clinicians should be familiar with the presentation of these tumours and have a high index of suspicion, since the potential for long-term survival following resection does exist. Wide surgical resection remains the cornerstone of sarcoma therapy. Complete characterization of tumour extent using echocardiography and CT/MRI is mandatory to achieve this goal. Radical resections such as 'bench surgery' and transplantation may reduce local recurrence, but the risk of metastatic disease remains. The clinical experience with such approaches is limited. The role of adjuvant therapy is not yet established. In no other field of cardiac surgery would a multidisciplinary approach be more useful, in achieving cure or long-term palliation.
- 1 June 2006
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 29 (6) , 925-932
Primary cardiac sarcoma
Primary malignant lesions of the heart are rare. Although myxomas have been extensively described, there is a paucity of large studies on non-myxomatous cardiac tumours. On the other hand, there are several case reports on specific histopathological variants, in small numbers. Consequently there exists no consensus on therapeutic modalities for cardiac sarcomas. The prognosis for these lesions remains dismal, despite the enhanced diagnostic ability of newer technology. The reasons for the dismal prognosis are (1) the advanced tumour stage at presentation, (2) non-specific symptomatolgy, (3) insufficient awareness of these lesions, due to their rarity, (4) delayed diagnosis and/or misdiagnosis, which leads to (5) advanced tumour stage at presentation. Thus a vicious cycle is created. This article addresses these issues, deals with the surgically relevant modes of presentation, rather than the histopathology, and reviews the diagnosis and management options for the various sarcomas, categorized by the site and extent of cardiac involvement. Clinicians should be familiar with the presentation of these tumours and have a high index of suspicion, since the potential for long-term survival following resection does exist. Wide surgical resection remains the cornerstone of sarcoma therapy. Complete characterization of tumour extent using echocardiography and CT/MRI is mandatory to achieve this goal. Radical resections such as 'bench surgery' and transplantation may reduce local recurrence, but the risk of metastatic disease remains. The clinical experience with such approaches is limited. The role of adjuvant therapy is not yet established. In no other field of cardiac surgery would a multidisciplinary approach be more useful, in achieving cure or long-term palliation.
- Open Access
- 1 January 2006
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 99 (1) , 38-39
Emergency resection of a carinal adenoma
- 1 January 2006
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 99 (1) , 38-39
Open AccessEmergency resection of a carinal adenoma
- Open Access
- 1 January 2006
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 99 (1) , 38-39
Emergency Resection of a Carinal Adenoma
- 1 January 2006
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 99 (1) , 38-39
Open AccessEmergency Resection of a Carinal Adenoma
- 1 November 2005
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 28 (5) , 705-710
Vasoplegic syndrome—the role of methylene blue
Vasoplegic syndrome is a recognized complication following cardiac surgery using cardiopulmonary bypass and is associated with increased morbidity and mortality. In several patients profound post-operative vasodilatation does not respond to conventional vasoconstrictor therapy. Methylene blue has been advocated as an adjunct to conventional vasoconstrictors in such situations. There is limited data pertaining to the use of methylene blue and a number of reports have been anecdotal observations. This article reviews the incidence and problems associated with the vasoplegic syndrome, the mechanism of action of methylene blue, its effects and adverse reactions and the literature supporting its intra-operative and post-operative use. In cases where first-line therapy fails, the use of methylene blue seems to be a potent approach to refractory vasoplegia. The early use of methylene blue may halt the progression of low systemic vascular resistance even in patients responsive to norepinephrine and mitigate the need for prolonged vasoconstrictor use. However, dosing regimens and protocols need to be clearly defined before widespread routine use. Whether methylene blue should be the first line of therapy in patients with vasoplegia is a matter of debate, and there is inadequate evidence to support its use as a first line drug. More scientific evidence is needed to define the role of MB in the treatment of catecholamine refractory vasoplegia.
- 1 November 2005
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 28 (5) , 705-710
Vasoplegic syndrome—the role of methylene blue
Vasoplegic syndrome is a recognized complication following cardiac surgery using cardiopulmonary bypass and is associated with increased morbidity and mortality. In several patients profound post-operative vasodilatation does not respond to conventional vasoconstrictor therapy. Methylene blue has been advocated as an adjunct to conventional vasoconstrictors in such situations. There is limited data pertaining to the use of methylene blue and a number of reports have been anecdotal observations. This article reviews the incidence and problems associated with the vasoplegic syndrome, the mechanism of action of methylene blue, its effects and adverse reactions and the literature supporting its intra-operative and post-operative use. In cases where first-line therapy fails, the use of methylene blue seems to be a potent approach to refractory vasoplegia. The early use of methylene blue may halt the progression of low systemic vascular resistance even in patients responsive to norepinephrine and mitigate the need for prolonged vasoconstrictor use. However, dosing regimens and protocols need to be clearly defined before widespread routine use. Whether methylene blue should be the first line of therapy in patients with vasoplegia is a matter of debate, and there is inadequate evidence to support its use as a first line drug. More scientific evidence is needed to define the role of MB in the treatment of catecholamine refractory vasoplegia.
- Open Access
- 1 November 2005
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 28 (5) , 731-735
Aortic valve replacement following previous coronary surgery
Aortic valve replacement following previous coronary surgery is associated with high risk. Major intraoperative problems include those associated with reentry, damage to the left internal mammary artery and myocardial protection. These factors influence operative results and eventual outcome to a large extent. The available evidence largely consists of retrospective series and case reports, with their own institutional bias, and it has been difficult to make specific recommendations on the basis of this evidence. However the article reviews the various surgical options available to manage this difficult subset of patients and discusses their pros and cons.
- 1 November 2005
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 28 (5) , 731-735
Open AccessAortic valve replacement following previous coronary surgery
Aortic valve replacement following previous coronary surgery is associated with high risk. Major intraoperative problems include those associated with reentry, damage to the left internal mammary artery and myocardial protection. These factors influence operative results and eventual outcome to a large extent. The available evidence largely consists of retrospective series and case reports, with their own institutional bias, and it has been difficult to make specific recommendations on the basis of this evidence. However the article reviews the various surgical options available to manage this difficult subset of patients and discusses their pros and cons.